SAN FRANCISCO, July 22, 2014 /PRNewswire/ -- Nektar
Therapeutics (Nasdaq: NKTR) will announce its financial results for
the second quarter ended June 30,
2014 on Thursday, July 31,
2014, after the close of U.S.-based financial markets.
Howard Robin, president and chief
executive officer, will host a conference call to review the
results beginning at 5:00 p.m. Eastern
Time (ET)/2:00 p.m. Pacific
Time (PT).
The press release and a live audio-only Webcast of the
conference call can be accessed through a link that is posted on
the home page and Investor Relations section of the Nektar website:
http://www.nektar.com. The web broadcast of the conference call
will be available for replay through Monday,
September 1, 2014.
To access the conference call, follow these instructions:
Dial: (877) 881-2183 (U.S.); (970) 315-0453
(international)
Passcode: 73168608 (Nektar Therapeutics is the host)
In the event that any non-GAAP financial measure is discussed on
the conference call that is not described in the press release, or
explained on the conference call, related information will be made
available on the Investor Relations page at the Nektar website as
soon as practical after the conclusion of the conference call.
About Nektar
Nektar Therapeutics (NASDAQ: NKTR) is a
biopharmaceutical company developing novel therapeutics based on
its advanced polymer conjugate technology platform. Nektar has a
robust R&D pipeline of potentially high-value therapeutics in
pain, oncology and other therapeutic areas. In the area of pain,
Nektar has an exclusive worldwide license agreement with
AstraZeneca for Movantik™ (naloxegol), an investigational drug
candidate, which has been filed for regulatory approvals in the
U.S., Europe and Canada as a once- daily, oral tablet for the
treatment of opioid-induced constipation. This agreement also
includes NKTR-119, an earlier stage development program that is a
co-formulation of naloxegol and an opioid. NKTR-181, a novel
mu-opioid analgesic molecule for chronic pain conditions, has
completed Phase 2 development. NKTR-171, a new sodium channel
blocker being developed as an oral therapy for the treatment of
peripheral neuropathic pain, is in Phase 1 clinical development. In
oncology, etirinotecan pegol (NKTR-102) is being evaluated in a
Phase 3 clinical study (the BEACON study) for the treatment of
metastatic breast cancer and is also in Phase 2 studies for the
treatment of lung and brain cancers. In anti-infectives, Amikacin
Inhale is in Phase 3 studies conducted by Bayer Healthcare as an
adjunctive treatment for intubated and mechanically ventilated
patients with Gram-negative pneumonia. Additional late-stage
development products that leverage Nektar's proprietary technology
platform include Baxter's BAX 855,
a longer-acting rFVIII program, which is in Phase 3 clinical
development for patients with hemophilia A.
Nektar's technology has enabled eight approved products in the
U.S. or Europe through
partnerships with leading biopharmaceutical companies, including
UCB's Cimzia® for Crohn's disease and
rheumatoid arthritis, Roche's PEGASYS® for
hepatitis C and Amgen's Neulasta® for
neutropenia.
Nektar is headquartered in San
Francisco, California, with additional operations in
Huntsville, Alabama and
Hyderabad, India. Further
information about the company and its drug development programs and
capabilities may be found online at http://www.nektar.com.
Contact: Jennifer Ruddock,
415-482-5585
SOURCE Nektar Therapeutics